HC Wainwright Brokers Reduce Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at HC Wainwright cut their Q2 2025 earnings estimates for shares of Corcept Therapeutics in a research report issued on Tuesday, May 6th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.08 for the quarter, down from their prior estimate of $0.47. HC Wainwright has a “Buy” rating and a $145.00 price target on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q3 2025 earnings at $0.32 EPS, Q4 2025 earnings at $0.70 EPS, FY2025 earnings at $1.29 EPS, FY2026 earnings at $3.56 EPS, FY2027 earnings at $7.33 EPS, FY2028 earnings at $10.47 EPS and FY2029 earnings at $12.96 EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Monday, May 5th. The biotechnology company reported $0.17 EPS for the quarter, meeting analysts’ consensus estimates of $0.17. The business had revenue of $157.21 million during the quarter, compared to analysts’ expectations of $177.93 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The business’s revenue was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.25 earnings per share.

Several other analysts have also recently issued reports on the stock. Piper Sandler upped their price objective on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the company an “overweight” rating in a research note on Thursday, April 3rd. Truist Financial set a $135.00 price target on Corcept Therapeutics in a research report on Tuesday. StockNews.com upgraded Corcept Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, Canaccord Genuity Group raised their target price on Corcept Therapeutics from $130.00 to $142.00 and gave the stock a “buy” rating in a research note on Tuesday, April 1st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $138.25.

Corcept Therapeutics Trading Up 1.3 %

Shares of CORT opened at $71.39 on Thursday. Corcept Therapeutics has a 52-week low of $25.35 and a 52-week high of $117.33. The stock has a market cap of $7.57 billion, a PE ratio of 56.66 and a beta of 0.22. The firm’s fifty day moving average is $66.58 and its two-hundred day moving average is $60.64. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 7,060 shares of the business’s stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $74.31, for a total value of $524,628.60. Following the sale, the insider now owns 5,487 shares of the company’s stock, valued at $407,738.97. The trade was a 56.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Sean Maduck sold 100,000 shares of the firm’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $100.54, for a total value of $10,054,000.00. Following the transaction, the insider now owns 85,622 shares of the company’s stock, valued at approximately $8,608,435.88. This represents a 53.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 236,738 shares of company stock worth $20,476,238. 20.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CORT. Franklin Resources Inc. lifted its stake in Corcept Therapeutics by 1.0% in the third quarter. Franklin Resources Inc. now owns 242,791 shares of the biotechnology company’s stock worth $10,998,000 after acquiring an additional 2,475 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Corcept Therapeutics by 43.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,070 shares of the biotechnology company’s stock valued at $11,712,000 after purchasing an additional 76,573 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Corcept Therapeutics by 20.3% during the 4th quarter. GAMMA Investing LLC now owns 2,996 shares of the biotechnology company’s stock worth $151,000 after purchasing an additional 506 shares during the last quarter. Burney Co. increased its holdings in Corcept Therapeutics by 9.1% in the fourth quarter. Burney Co. now owns 473,821 shares of the biotechnology company’s stock valued at $23,876,000 after buying an additional 39,657 shares during the last quarter. Finally, USA Financial Formulas acquired a new stake in Corcept Therapeutics in the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.